MedPage Today on MSN2d
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery DiseaseCHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
Licensee patent challenges represent a critical intersection between contractual agreements and patent law. This concept, ...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. To be known as Viela Bio, the spin-out ...
In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 billion. However many analysts felt the company had paid far too much ...
As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...
There's good news for white-collar workers who feel job pressure © 2025 American City Business Journals. All rights reserved. Use of and/or registration on any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback